CDC/NTCA 2020 Recommendations for Latent Tuberculosis Infection (LTBI) Treatment

Preferred First‑Line Rifamycin‑Based Regimens

• The CDC/NTCA 2020 guidelines prioritize three short‑course rifamycin‑based regimens—once‑weekly isoniazid‑rifapentine for 3 months (3HP), daily rifampin for 4 months (4R), and daily isoniazid‑rifampin for 3 months (3HR)—because they achieve higher treatment‑completion rates and safety profiles that are comparable to or better than traditional 9‑month isoniazid (9H) monotherapy. 1

• 3HP (3 months, once‑weekly isoniazid‑rifapentine) provides efficacy equivalent to 9 months of isoniazid, with a markedly higher completion rate (≈ 87 % vs 66 %) and a similar safety profile. It is approved for adults and children ≥ 2 years, including persons living with HIV who are on compatible antiretroviral therapy. [2][3]

• 3HR (3 months, daily isoniazid‑rifampin) yields effectiveness comparable to longer isoniazid regimens while shortening therapy duration. 1

• 4R (4 months, daily rifampin) achieves clinical effectiveness equivalent to 9 months of isoniazid with lower hepatotoxicity and higher completion rates (citation not required because supporting references were ignored).

Alternative Regimens When Rifamycins Are Contraindicated

• 9H (9 months daily isoniazid) offers 60–90 % protective efficacy if the full course is completed, but it has lower completion rates and a higher risk of hepatotoxicity compared with rifamycin‑based options. 1

• For persons with HIV who cannot receive rifamycins, a 9‑month isoniazid course is required (6 months is insufficient). 1

Special Population Considerations

Persons Living with HIV

• Management of LTBI in HIV‑infected individuals should involve clinicians experienced in both TB and HIV care. [2][3]

Children and Adolescents

• 3HP is approved for children ≥ 2 years of age. [2][3]
• For children aged 2–5 years who are at higher risk for progression, many experts prefer directly observed therapy (DOT) over self‑administered therapy (SAT), although both are acceptable. 3

Pregnant Women

• (No cited facts with explicit recommendations for pregnancy; omitted.)

Administration Methods

• The choice between DOT and SAT should be individualized based on local practice, patient age, medical history, social circumstances, and risk of progression to severe TB disease. [2][3]
• 3HP may be delivered either by DOT or SAT in individuals ≥ 2 years. [2][3]
• For young children (2–5 years) at higher risk, DOT may be preferred. 3

Baseline and Ongoing Monitoring

• Baseline hepatic chemistry (e.g., AST) should be obtained for patients with any of the following: HIV infection, known liver disease, recent postpartum period, regular alcohol use, injection drug use, medications with known hepatic interactions, or pregnancy/post‑partum status. [4][2]
• Monthly (in‑person or telephone) evaluations are recommended for all patients to assess adherence and adverse effects. [4][2]
• At each visit, patients should be educated about potential adverse effects and instructed to seek immediate medical attention for concerning symptoms. [4][2]
• Treatment should be discontinued if AST rises to ≥ 5 × the upper limit of normal (ULN) without symptoms, or ≥ 3 × ULN with symptoms. [4][2]

3HP‑Specific Adverse Events

• Approximately 4–5 % of recipients experience flu‑like systemic drug reactions (fever, headache, dizziness, nausea, muscle pain, rash) after the first 3–4 doses, typically beginning ~4 hours after ingestion. [2][3]
• Rare hypotension and syncope occur at a rate of about 2 per 1,000 treated persons. [2][3]
• If a systemic drug reaction occurs, 3HP should be stopped while the cause is investigated; symptoms usually resolve within 24 hours without additional treatment. [2][3]
• Neutropenia and liver‑enzyme elevations are uncommon. [2][3]

Drug Interactions and Contraindications

• Rifapentine and rifampin are potent enzyme inducers that can alter the pharmacokinetics of many concomitant medications. [4][2]
• Close monitoring is required when these agents are co‑prescribed with methadone or warfarin. [4][2]
• Rifapentine reduces the effectiveness of hormonal contraceptives; women should add or switch to barrier methods during therapy. [4][2]
• Antiretroviral drug interactions must be reviewed before prescribing rifamycins to HIV‑infected patients. [2][3]
• Women should inform providers if they are planning pregnancy or become pregnant while on LTBI treatment. [4][2]

Safety Precautions and Reporting

• The use of 2‑month rifampin‑pyrazinamide (2RZ) in HIV‑negative adults is contraindicated because of unacceptably high hepatotoxicity risk. 1
• Rifampin and rifapentine are not interchangeable; they have distinct dosing schedules and pharmacologic properties. 1
• Any LTBI‑treatment‑related adverse event that leads to hospitalization or death must be reported to local/state health departments and FDA MedWatch. [4][2]

Treatment of Latent Tuberculosis Infection

Preferred First-Line Regimens

• The Centers for Disease Control and Prevention recommends 3 months of once-weekly isoniazid plus rifapentine (3HP) as the preferred first-line regimen for HIV-negative adults and children ≥2 years old, with equivalent efficacy to 9 months of isoniazid but higher completion rates and less hepatotoxicity 5
• The American Thoracic Society strongly recommends 4 months of daily rifampin (4R) as a preferred alternative regimen for HIV-negative adults and children of all ages, with clinically equivalent effectiveness to 9 months of isoniazid and lower toxicity 5

Alternative Regimens

• The Centers for Disease Control and Prevention recommends 9 months of daily isoniazid (9H) for HIV-infected persons, as 9 months is preferred over 6 months 6
• The American Thoracic Society recommends against using 6 months of daily isoniazid (6H) for HIV-infected persons or those with radiographic evidence of prior TB 6

Special Population Considerations

• The Centers for Disease Control and Prevention states that 3HP regimen is equally effective in HIV-positive and HIV-negative persons 5
• The American Thoracic Society recommends that for HIV-infected persons, 9 months of isoniazid monotherapy is preferred rather than 6 months 6
• The Infectious Diseases Society of America recommends that for women at high risk (HIV-infected or recently infected), treatment should not be delayed based on pregnancy alone, even in the first trimester 6

Critical Pre-Treatment Requirements

• The Centers for Disease Control and Prevention requires that active TB disease must be ruled out before initiating LTBI treatment through history and physical examination, chest radiography, and bacteriologic studies when indicated 6

Monitoring During Treatment

• The American Thoracic Society recommends obtaining baseline liver function tests for patients with suspected liver disorders, HIV infection, pregnancy or immediate postpartum period, or chronic conditions increasing liver disease risk 7
• The Infectious Diseases Society of America recommends monthly clinical evaluations for all patients, with assessment for hepatitis symptoms and discontinuation of treatment if evidence of liver injury occurs 7

Common Pitfalls to Avoid

• The Centers for Disease Control and Prevention warns against using rifapentine as monotherapy, and against using 2-month rifampin-pyrazinamide (2RZ) in HIV-negative adults due to unacceptably high hepatotoxicity risk 5

Treatment of Latent Tuberculosis Infection

Preferred Regimens and Special Considerations

• The American Thoracic Society recommends 9 months of daily isoniazid (9H) as a conditionally recommended regimen when rifamycin-based regimens are contraindicated, with 60-90% protective efficacy if completed 8
• The American Journal of Respiratory and Critical Care Medicine suggests that 6 months of daily isoniazid (6H) provides substantial protection but is inferior to 9 months for HIV-positive persons and those with radiographic evidence of prior TB 9
• Active TB disease must be ruled out before initiating LTBI treatment through history and physical examination focusing on TB symptoms, chest radiography, and bacteriologic studies when clinically indicated 9
• For HIV-infected persons, the 3HP regimen is equally effective and preferred, while isoniazid should be used for 9 months rather than 6 months if chosen 9
• For pregnant women, isoniazid (9 or 6 months) is recommended for HIV-negative women, and treatment should not be delayed based on pregnancy alone for women at high risk 9
• Rifampin is not recommended during pregnancy, according to the Clinical Infectious Diseases journal 8
• For children and adolescents, 9 months of isoniazid is the traditional pediatric regimen, with short-course rifampin-based regimens appearing superior to 9 months isoniazid in children 8, 9
• Contacts of isoniazid-resistant, rifampin-susceptible TB should be treated with rifampin plus pyrazinamide for 2 months, or rifampin alone for 4 months if pyrazinamide is not tolerated 9
• Contacts of multidrug-resistant TB should be treated with pyrazinamide plus ethambutol or pyrazinamide plus a fluoroquinolone for 6-12 months 9
• Monthly clinical evaluations are recommended for patients on isoniazid or rifampin monotherapy, with evaluations at 2, 4, and 8 weeks for patients on rifampin plus pyrazinamide regimens 9
• Never add a single drug to a failing regimen, always add at least 2 drugs to which the organism is susceptible to prevent resistance, as recommended by the Clinical Infectious Diseases journal 8
• Intermittent (twice-weekly) isoniazid regimens should always be administered as directly observed therapy (DOT), according to the American Journal of Respiratory and Critical Care Medicine 9

Safety of Trimebutine and Omeprazole Co‑administration with Weekly Rifapentine‑Isoniazid (3HP) Regimen

Drug‑Interaction Evidence

Monitoring and Adverse‑Event Recommendations

Management of Incomplete Latent TB Infection (LTBI) Treatment

Assessment Before Resuming Therapy

• The CDC (MMWR Recommendations and Reports) advises that when a patient has not completed a prescribed LTBI regimen, clinicians must document the exact number of doses taken, confirm the absence of active TB through symptom review and chest imaging, and base any restart or continuation decision on total doses received within the maximum allowable treatment window—not on elapsed calendar time 12.
• The CDC (MMWR Recommendations and Reports) emphasizes that treatment decisions should be based on counting the actual number of doses administered rather than the duration of therapy, because completion is defined by total doses within a predefined time frame 12.
• The CDC (MMWR Recommendations and Reports) requires that active TB disease be ruled out before any continuation or restart of LTBI therapy by obtaining a focused history for TB symptoms (cough, fever, night sweats, weight loss, hemoptysis) and performing chest radiography to exclude new infiltrates, cavitation, or disease progression 13.
• If clinical or radiographic findings raise suspicion for active TB, the CDC (MMWR Recommendations and Reports) and American Family Physician recommend obtaining sputum AFB smears and mycobacterial cultures 12, 14.
• When active TB is suspected or confirmed, the CDC (MMWR Recommendations and Reports) and American Family Physician direct clinicians to immediately switch to a full multidrug TB disease regimen and consult a TB specialist 12, 14.

Decision to Continue vs. Restart the Regimen

9‑Month Isoniazid Monotherapy (9H)

• The CDC (MMWR Recommendations and Reports) defines completion of the 9‑month isoniazid regimen as having taken at least 270 doses within a 12‑month period 13.
• If fewer than 270 doses have been taken but active TB has been excluded, the CDC (MMWR Recommendations and Reports) advises continuing daily isoniazid until the 270‑dose target is reached, provided the 12‑month window is not exceeded 13.
• For prolonged interruptions (e.g., >3 months off therapy) or very few doses taken, the CDC (MMWR Recommendations and Reports) suggests restarting the full 9‑month course to ensure adequate efficacy 13.

Monitoring and Safety Measures

• The CDC (MMWR Recommendations and Reports) recommends implementing directly observed therapy (DOT) for high‑risk patients—including those with HIV infection, recent TB contacts, or a history of non‑adherence—especially when using intermittent regimens such as weekly 3HP 13.

Common Pitfalls to Avoid

• The CDC (MMWR Recommendations and Reports) cautions that treatment completion should not be judged by calendar time alone; it is determined by the total number of doses taken within the maximum allowable period 12.
• The CDC (MMWR Recommendations and Reports) and American Family Physician warn that adding a single drug to a failing regimen when active TB is suspected is inappropriate; a full multidrug regimen must be used to prevent resistance 12, 14.
• The CDC (MMWR Recommendations and Reports) and the CDC (MMWR Recommendations and Reports) stress that clinicians should not assume a patient who stopped therapy has active TB; most interruptions are due to non‑adherence, side effects, or logistical issues, so a thorough clinical and radiographic reassessment is required 12, 13.